# Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

> **NCT01515020** · PHASE3 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 10 (actual)

## Conditions studied

- Nosocomial Infection
- Healthcare-associated Infection

## Interventions

- **DRUG:** vancomycin monotherapy
- **DRUG:** daptomycin monotherapy

## Key facts

- **NCT ID:** NCT01515020
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-06
- **Final completion:** 2014-07
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** lack of inclusion
- **Last updated:** 2014-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515020, "Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01515020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*